Literature DB >> 33523256

The relevance of multiple sclerosis cortical lesions on cortical thinning and their clinical impact as assessed by 7.0-T MRI.

Constantina A Treaba1,2, Elena Herranz1,2, Valeria T Barletta1,2, Ambica Mehndiratta1, Russell Ouellette1, Jacob A Sloane3, Eric C Klawiter4, Revere P Kinkel5, Caterina Mainero6,7.   

Abstract

OBJECTIVE: This study aimed to investigate at 7.0-T MRI a) the role of multiple sclerosis (MS) cortical lesions in cortical tissue loss b) their relation to neurological disability.
METHODS: In 76 relapsing remitting and 26 secondary progressive MS patients (N = 102) and 56 healthy subjects 7.0-T T2*-weighted images were acquired for lesion segmentation; 3.0-T T1-weighted structural scans for cortical surface reconstruction/cortical thickness estimation. Patients were dichotomized based on the median cortical lesion volume in low and high cortical lesion load groups that differed by age, MS phenotype and degree of neurological disability. Group differences in cortical thickness were tested on reconstructed cortical surface. Patients were evaluated clinically by means of the Expanded Disability Status Scale (EDSS).
RESULTS: Cortical lesions were detected in 96% of patients. White matter lesion load was greater in the high than in the low cortical lesion load MS group (p = 0.01). Both MS groups disclosed clusters (prevalently parietal) of cortical thinning relative to healthy subjects, though these regions did not show the highest cortical lesion density, which predominantly involved frontal regions. Cortical thickness decreased on average by 0.37 mm, (p = 0.002) in MS patients for each unit standard deviation change in white matter lesion volume. The odds of having a higher EDSS were associated with cortical lesion volume (1.78, p = 0.01) and disease duration (1.15, p < 0.001).
CONCLUSION: Cortical thinning in MS is not directly related to cortical lesion load but rather with white matter lesion volume. Neurological disability in MS is better explained by cortical lesion volume assessment.

Entities:  

Keywords:  Brain; Cortical atrophy; Cortical lesions; Multiple sclerosis; Ultra-high field (7 T)

Year:  2021        PMID: 33523256     DOI: 10.1007/s00415-021-10400-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  42 in total

1.  Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

Authors:  Maria Pia Sormani; Laura Bonzano; Luca Roccatagliata; Gary R Cutter; Gian Luigi Mancardi; Paolo Bruzzi
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

2.  Spinal cord neuronal pathology in multiple sclerosis.

Authors:  Christopher P Gilmore; Gabriele C DeLuca; Lars Bö; Trudy Owens; James Lowe; Margaret M Esiri; Nikos Evangelou
Journal:  Brain Pathol       Date:  2008-12-19       Impact factor: 6.508

Review 3.  MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials.

Authors:  Maria Pia Sormani; Paolo Bruzzi
Journal:  Lancet Neurol       Date:  2013-06-03       Impact factor: 44.182

Review 4.  Brain MRI atrophy quantification in MS: From methods to clinical application.

Authors:  Maria A Rocca; Marco Battaglini; Ralph H B Benedict; Nicola De Stefano; Jeroen J G Geurts; Roland G Henry; Mark A Horsfield; Mark Jenkinson; Elisabetta Pagani; Massimo Filippi
Journal:  Neurology       Date:  2016-12-16       Impact factor: 9.910

5.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

Authors:  J W Peterson; L Bö; S Mörk; A Chang; B D Trapp
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

6.  Cortical demyelination and diffuse white matter injury in multiple sclerosis.

Authors:  Alexandra Kutzelnigg; Claudia F Lucchinetti; Christine Stadelmann; Wolfgang Brück; Helmut Rauschka; Markus Bergmann; Manfred Schmidbauer; Joseph E Parisi; Hans Lassmann
Journal:  Brain       Date:  2005-10-17       Impact factor: 13.501

Review 7.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

8.  New insights into the burden and costs of multiple sclerosis in Europe.

Authors:  Gisela Kobelt; Alan Thompson; Jenny Berg; Mia Gannedahl; Jennifer Eriksson
Journal:  Mult Scler       Date:  2017-02-01       Impact factor: 6.312

Review 9.  Evolution of clinical trials in multiple sclerosis.

Authors:  Yinan Zhang; Amber Salter; Erik Wallström; Gary Cutter; Olaf Stüve
Journal:  Ther Adv Neurol Disord       Date:  2019-02-21       Impact factor: 6.570

Review 10.  Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.

Authors:  Alberto Gajofatto; Massimiliano Calabrese; Maria Donata Benedetti; Salvatore Monaco
Journal:  Dis Markers       Date:  2013-11-10       Impact factor: 3.434

View more
  1 in total

1.  Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis.

Authors:  Erin S Beck; Josefina Maranzano; Nicholas J Luciano; Prasanna Parvathaneni; Stefano Filippini; Mark Morrison; Daniel J Suto; Tianxia Wu; Peter van Gelderen; Jacco A de Zwart; Samson Antel; Dumitru Fetco; Joan Ohayon; Frances Andrada; Yair Mina; Chevaz Thomas; Steve Jacobson; Jeff Duyn; Irene Cortese; Sridar Narayanan; Govind Nair; Pascal Sati; Daniel S Reich
Journal:  Mult Scler       Date:  2022-02-10       Impact factor: 5.855

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.